Epstein Secrets

ODHUE,ALBERT BREEDEN,RAMON W LEHMAN,CHRISTOPHER M DONNELLEY,MRS ELLIOTT R BENSON,ELIZ

TOWN OF PALM BEACH SHARF,MICHAEL MERCK,GEORGE F OXLEY,JOHN C IOVINO,JUDITH

d Scheme Alabama Live (11/30, Robinson) reported that Christopher Montalbano pleaded guilty to a bank fraud scheme and money laundering in Alabama. Christopher and his father, Gus Anthony Montalbano, were indicted earlier this year on a 26-count indictment in federal court charging them with conspiracy to c

d 'El Chapo' to Three Years in Prison • CNN Suspends Chris Cuomo for Helping Brother in Scandal • US Panel Backs First-Of-A-Kind COVID-19 Pill From Merck CAPITOL VIOLENCE NEWS • Prosecutors Charge Man Who Allegedly Assaulted Police at the US Capitol and Brought Hatchets to FBI Headquarters • Meadow

losures section of this report, the cettifying analyst's coverage universe can be found on M. Morgan's research website, Coverage Universe: Schott, Christopher: AbbVie (ABBV), Actavis plc (ACT), Allergan (AGN), Amarin Corporation (AMRN), Bristol-Myers Squibb Company (BMY), Eli Lilly & Company (LLY), Endo In

J.P.Morgan North America Equity Research O2 June 2014 • Merck & Co., Inc. Pushing Ahead Aggressively in PD-1 Development We attended Merck's ASCO analyst meeting today where the company reviewed new data and development plans for its PD-1 (pembrolizumab). Overall, we increasingly see M

sclosures section of this report, the certifying analyst's coverage universe can be found on Morgan's research website, Coverage Universe: Schott, Christopher: AbbVie (ABBV), Allergan plc (AGN), Bristol-Myers Squibb Company (BMY), Coheres (CHRS), Eli Lilly & Company (LLY), Endo International PLC (ENDP), Im

truda label further reinforces our view that Opdivo will maintain a clear leadership position in the NSCLC marketplace. Overall, we continue to see Merck as a competitive I/O player with a lead in multiple tumors with large unmet need such as HNSCC and colorectal tumors harboring MMR mutations. • Ke